A2 - Price List - Reference Lab Testing Services - Revised 3-12-2021 - ELP.xlsx
XLSX spreadsheet 27 KB Posted
- Solicitation number
- 36C25721Q0374
View the file
Other files
Show all 11
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Sheet1
| Estimated | ||||||
| SUBLINE | Turn-Around | Annual | Extended | |||
| ITEM # | Test Description | CPT CODE(S) | Time (Days) | Quantity | Unit Price | Price |
| 0001AA | 17-HYDROXYPROGESTERONE | 12 | ||||
| 0001AB | ACETYLCHOLINE RECEPTOR BINDING ANTIBODY | 12 | ||||
| 0001AC | 5' NUCLEOTIDASE | 12 | ||||
| 0001AD | ABL KINASE DOMAIN MUTATION IN CML, CELL-BASED | 12 | ||||
| 0001AE | ACETYLCHOLINE RECEPTOR BINDING ANTIBODY | 12 | ||||
| 0001AF | 5-HYDROXYINDOLEACETIC ACID (5-HIAA), RANDOM URINE | 12 | ||||
| 0001AG | ACTH, PLASMA | 12 | ||||
| 0001AH | ADVANCED LIPID PANEL WITH INFLAMMATION, CARDIO IQ® | 12 | ||||
| 0001AJ | ACTIN (SMOOTH MUSCLE) ANTIBODY (IGG) | 12 | ||||
| 0001AK | ALDOLASE | 12 | ||||
| 0001AL | ALDOSTERONE/PLASMA RENIN ACTIVITY RATIO, LC/MS/MS | 12 | ||||
| 0001AM | ALPHA-1-ANTITRYPSIN (AAT) PHENOTYPE | 12 | ||||
| 0001AN | ALKALINE PHOSPHATASE ISOENZYMES | 12 | ||||
| 0001AP | ALPHA-1-ANTITRYPSIN, QUANTITATIVE | 12 | ||||
| 0001AQ | ALPHA-FETOPROTEIN, TUMOR MARKER | 12 | ||||
| 0001AR | ALPHA-GLOBIN COMMON MUTATION ANALYSIS | 12 | ||||
| 0001AS | AMITRIPTYLINE | 12 | ||||
| 0001AT | ANA SCR,IFA,RFL T/P/MPXAB | 744 | ||||
| 0001AU | ANASCR,RF T/P/MPX/IDENTRA | 312 | ||||
| 0001AV | ANCA SCREEN WITH REFLEX TO ANCA TITER | 60 | ||||
| 0001AW | ANDROSTENEDIONE | 12 | ||||
| 0001AX | ANTI-MULLERIAN HORMONE (AMH , Female | 12 | ||||
| 0001AY | ANGIOTENSIN CONVERTING ENZYME | 60 | ||||
| 0001AZ | APOLIPOPROTEIN EVALUATION | 12 | ||||
| 0001BA | ASPERGILLUS ANTIBODIES, IMMUNODIFFUSION, SERUM | 12 | ||||
| 0001BB | B-CELL CLONALITY PANEL (IGH, IGK) | 48 | ||||
| 0001BC | ANTITHROMBIN III ACTIVITY [216] | 108 | ||||
| 0001BD | BETA-2-GLYCOPROTEIN I ANTIBODIES (IGG, IGA, IGM | 12 | ||||
| 0001BE | BLASTOMYCES ANTIBODY, IMMUNODIFFUSION, SERUM | 24 | ||||
| 0001BF | BCR-ABL1 GENE REARRANGEMENT, QUANTITATIVE PCR | 60 | ||||
| 0001BG | BK VIRUS DNA, QUANTITATIVE REAL-TIME PCR, PLASMA | 24 | ||||
| 0001BH | BRCAVANTAGE(R | 12 | ||||
| 0001BJ | BLASTOMYCES ANTIBODY IMMUNODIFFUSION, SERUM | 24 | ||||
| 0001BK | BORDETELLA PERTUSSIS TOXIN (PT | 12 | ||||
| 0001BL | Bordetella Pertussis/Parapertussis DNA, Qualitative, RT-PCR | 24 | ||||
| 0001BM | BUPRENORPHINE SCREEN, URINE | 24 | ||||
| 0001BN | C-PEPTIDE | 72 | ||||
| 0001BP | C-REACTIVE PROTEIN (CRP) | 456 | ||||
| 0001BQ | CA 19-9 | 72 | ||||
| 0001BR | CALCIUM, 24-HOUR URINE WITHOUT CREATININE | 36 | ||||
| 0001BS | CA 125 | 36 | ||||
| 0001BT | CALCIUM, IONIZED | 84 | ||||
| 0001BU | CALRETICULIN (CALR) MUTATION ANALYSIS | 36 | ||||
| 0001BV | CARBAMAZEPINE, TOTAL | 96 | ||||
| 0001BW | CARDIO IQ(R) APOE GENOTYPE | 12 | ||||
| 0001BX | CARDIO IQ(R) LIPOPROTEIN FRACTIONATION, ION MOBILITY | 12 | ||||
| 0001BY | CATECHOLAMINES, FRACTIONATED, RANDOM URINE | 12 | ||||
| 0001BZ | CARDIOLIPIN ANTIBODIES (IGA, IGG, IGM) | 120 | ||||
| 0001CA | Cathecholamines, Fractionated, 24-Hour Urine With Creatinine | 12 | ||||
| 0001CB | CEA | 72 | ||||
| 0001CC | CELIAC DISEASE COMP PANEL W/GLIADIN AB (IGG) | 12 | ||||
| 0001CD | CELIAC DISEASE COMPREHENSIVE PANEL | 96 | ||||
| 0001CE | CLOBAZAM, SERUM/PLASMA | 12 | ||||
| 0001CF | CERULOPLASMIN | 132 | ||||
| 0001CG | CHLAMYDIA/NEISSERIA GONORRHOEAE RNA, TMA, UROGENITAL | 12 | ||||
| 0001CH | CHLAMYDIA/NEISSERIA GONORRHOEAE RNA, TMA, RECTAL | 12 | ||||
| 0001CJ | CHLAMYDIA/NEISSERIA GONORRHOEAE RNA, TMA, THROAT | 12 | ||||
| 0001CK | COLD HEMAGGLUTININS | 12 | ||||
| 0001CL | CHROMOSOME ANALYSIS, HEMATOLOGIC MALIGNANCY | 12 | ||||
| 0001CM | COCCIDIOIDES ANTIBODIES TO TP & F ANTIGENS, ID | 12 | ||||
| 0001CN | COCCIDIOIDES ANTIBODIES (IGG, IGM), IMMUNODIFFUSION | 36 | ||||
| 0001CP | COCCIDIOIDES ANTIBODY, COMPLEMENT FIXATION, SERUM | 12 | ||||
| 0001CQ | COCCIDIOIDES ANTIBODY ID SERUM | 24 | ||||
| 0001CR | CHLORIDE, RANDOM URINE WITHOUT CREATININE | 36 | ||||
| 0001CS | CHROMOGRANIN A | 24 | ||||
| 0001CT | COLLAGEN TYPE I C-TELOPEPTIDE (CTX) | 36 | ||||
| 0001CU | COMPLEMENT COMPONENT C3C & C4C | 36 | ||||
| 0001CV | COPEPTIN | 24 | ||||
| 0001CW | COPPER, RANDOM URINE | 12 | ||||
| 0001CX | COPPER | 48 | ||||
| 0001CY | CORTISOL FREE, 24 HR URINE | 12 | ||||
| 0001CZ | CRYPTOCOCCAL ANTIGEN,LATEX SCREEN W/REFLEX TO TITER | 24 | ||||
| 0001DA | CULTURE, YEAST, W/ID AND SUSCEPT, COMPREHENSIVE | 12 | ||||
| 0001DB | CRYPTOCOCCUS ANTIBODY | 24 | ||||
| 0001DC | CREATINE KINASE ISOENZYMES (CK ISOENZYMES | 24 | ||||
| 0001DD | CORTISOL, TOTAL | 84 | ||||
| 0001DE | CYCLOSPORINE A TROUGH, LCMSMS, BLOOD | 12 | ||||
| 0001DF | CYCLIC CITRULLINATED PEPTIDE (CCP) ANTIBODY (IGG) | 156 | ||||
| 0001DG | Cystatin C With Glomerular Filtration Rate, Estimated (EGFR) | 324 | ||||
| 0001DH | CYTOMEGALOVIRUS ANTIBODIES (IGG, IGM) | 48 | ||||
| 0001DJ | DIPHTHERIA AND TETANUS ANTITOXOIDS | 12 | ||||
| 0001DK | DHEA SULFATE, IMMUNOASSAY | 24 | ||||
| 0001DL | DIGOXIN | 60 | ||||
| 0001DM | DEXAMETHASONE | 12 | ||||
| 0001DN | DIHYDROTESTOSTERONE | 12 | ||||
| 0001DP | DNA (DS) ANTIBODY | 36 | ||||
| 0001DQ | DRUG ABUSE SCREEN 5, WITHOUT CONFIRMATION, SERUM | 36 | ||||
| 0001DR | DRUG MONITORING PROF. 1,PLUS PROPOXYPHENE W/CONF | 2292 | ||||
| 0001DS | ENDOMYSIAL ANTIBODY SCREEN (IGA , With Reflex to Titer | 12 | ||||
| 0001DT | EPIDERMAL ANTIBODIES WITH REFLEX TO TITER | 12 | ||||
| 0001DU | Drug Monitoring, Methylphenidate Metabolite, QN, Urine | 12 | ||||
| 0001DV | ENTAMOEBA HISTOLYTICA ANTIBODY (IGG), ELISA | 12 | ||||
| 0001DW | EPSTEIN-BARR VIRUS ANTIBODY PANEL | 48 | ||||
| 0001DX | Epstein-Barr Virus Panel Capsid Antigen (VCA) AB (IGA) | 12 | ||||
| 0001DY | Epstein-Barr Virus Panel Viral Capsid Antigen (VCA) Antibody (IGG) | 12 | ||||
| 0001DZ | Drug Toxicology Monitoring Alcohol Metab, W/ Confirm, Urine | 240 | ||||
| 0001EA | Epstein-Barr Virus Viral Capsid Antigen (VCA) Antibody (IGM) | 24 | ||||
| 0001EB | ERYTHROPOIETIN | 84 | ||||
| 0001EC | ESTRADIOL, ULTRASENSITIVE, LC/MS | 12 | ||||
| 0001ED | ESTRADIOL | 84 | ||||
| 0001EF | ESTROGENS, FRACTIONATED, LC/MS | 24 | ||||
| 0001EG | ESTRONE, Antibodies (IGG, IGA) | 12 | ||||
| 0001EH | EVEROLIMUS, LC/MS/MS, BLOOD | 36 | ||||
| 0001EJ | FACTOR VIII ACTIVITY, CLOTTING | 12 | ||||
| 0001EK | FACTOR XII ACTIVITY | 12 | ||||
| 0001EL | FACTOR X ACTIVITY, CLOTTING | 12 | ||||
| 0001EM | FACTOR V (LEIDEN) MUTATION ANALYSIS | 84 | ||||
| 0001EN | FACTOR VIII INHIBITOR PANEL | 12 | ||||
| 0001EP | FIBRINOGEN ACTIVITY, CLAUSS | 96 | ||||
| 0001EQ | FREE KAPPA & LAMBDA, WITH K/L RATIO, SERUM | 24 | ||||
| 0001ER | FRUCTOSAMINE | 36 | ||||
| 0001ES | FTA-ABS | 12 | ||||
| 0001ET | FSH (FOLLICLE STIMULATING HORMONE) | 276 | ||||
| 0001EU | GABAPENTIN | 12 | ||||
| 0001EV | GLIADIN (DEAMIDATED | 12 | ||||
| 0001EW | GASTRIC PARIETAL CELL ANTIBODY, ELISA | 48 | ||||
| 0001EX | GROWTH HORMONE | 12 | ||||
| 0001EY | Glucose-6-Phosphate Dehydrogenase, (G-6-PD),Quantitative | 36 | ||||
| 0001EZ | GLUTAMIC ACID DECARBOXYLASE-65 ANTIBODY | 12 | ||||
| 0001FA | HAPTOGLOBIN | 252 | ||||
| 0001FB | HEAVY METALS PANEL (VENOUS) | 36 | ||||
| 0001FC | HEAVY METALS PANEL, RANDOM URINE WITH CADMIUM | 276 | ||||
| 0001FD | HELICOBACTER PYLORI, UREA BREATH TEST | 144 | ||||
| 0001FE | HEMOGLOBINOPATHY EVALUATION | 84 | ||||
| 0001FF | HEP C Viral RNA Genotype, LIPA W/ RFX To HCV NS5A Drug Resist | 60 | ||||
| 0001FG | HEPATITIIS D VIRUS RNA, QUANTITATIVE, REAL-TIME PCR | 24 | ||||
| 0001FH | HEPATITIS A ANTIBODY, TOTAL | 144 | ||||
| 0001FJ | HEPATITIS A ANTIBODY, TOTAL W/REFLEX IGM | 12 | ||||
| 0001FK | HEPATITIS A IGM ANTIBODY | 48 | ||||
| 0001FL | HEPATITIS B CORE ANTIBODIES (IGM, TOTAL) | 240 | ||||
| 0001FM | Hepatitis B Surface Antigen With Reflex To Confirmation | 1068 | ||||
| 0001FN | HEPATITIS B VIRUS DNA, QUANTITATIVE, REAL-TIME PCR | 108 | ||||
| 0001FP | HEPATITIS BE ANTIBODY | 72 | ||||
| 0001FQ | HEPATITIS BE ANTIGEN | 60 | ||||
| 0001FR | Hepatitis C Viral RNA Genotype 1 NS5A Drug Resistance | 12 | ||||
| 0001FS | HEPATITIS D VIRUS (HDV | 12 | ||||
| 0001FT | HEPATITIS C VIRAL RNA QUANTITATIVE, REAL-TIME PCR | 300 | ||||
| 0001FU | HEREDITARY HEMOCHROMATOSIS DNA MUTATION ANALYSIS | 48 | ||||
| 0001FV | Herpes Simplex Virsus 1 and 2 (IGG), Type-Specific Antibodies, IGE (2546 | 72 | ||||
| 0001FW | HERPES SIMPLEX VIRUS 1/2 AB (IGM), IFA W/RFX TO TITER, SER | 84 | ||||
| 0001FX | HERPES SIMPLEX VIRUS, TYPE 1 AND 2 DNA, QUAL REAL-TIME PCR | 84 | ||||
| 0001FY | HETEROPHILE, MONO SCREEN | 12 | ||||
| 0001FZ | HISTOPLASMA ANTIBODY IMMUNODIFFUSION, SERUM | 24 | ||||
| 0001GA | HIV 1 RNA, QUANTITATIVE REAL-TIME PCR | 228 | ||||
| 0001GB | HIV-1 GENOTYPE | 24 | ||||
| 0001GC | HIV-1 INTEGRASE GENOTYPE | 12 | ||||
| 0001GD | HIV-1/2 Antigen and Antibodies, 4th Generation, W/ Reflexes | 24 | ||||
| 0001GE | HLA TYPING FOR CELIAC DISEAS | 12 | ||||
| 0001GF | HLA-A,B,C INTERMEDIATE RESOLUTION TYPING | 12 | ||||
| 0001GG | HLA-DR/DQ INTERMEDIATE RESOLUTION TYPING | 12 | ||||
| 0001GH | HLA-B5701 TYPING | 12 | ||||
| 0001GJ | HLA-B27 ANTIGEN | 24 | ||||
| 0001GK | HORSE SERUM (E205 | 12 | ||||
| 0001GL | HUNTINGTON DISEASE MUTATION ANALYSI | 12 | ||||
| 0001GM | IGF-1, LC/MS | 12 | ||||
| 0001GN | HOMOCYSTEINE | 120 | ||||
| 0001GP | HU ANTIBODY SCREEN WITH REFLEX TO TITER AND WESTERN BLOT | 12 | ||||
| 0001GQ | IMMUNOFIXATION (IFE), URINE | 84 | ||||
| 0001GR | IMMUNOFIXATION, SERUM | 48 | ||||
| 0001GS | IMMUNOGLOBULIN A | 12 | ||||
| 0001GT | IMMUNOGLOBULIN E | 84 | ||||
| 0001GU | IMMUNOGLOBULIN G SUBCLASSES PANEL | 24 | ||||
| 0001GV | IMMUNOGLOBULIN PANEL, SERUM | 24 | ||||
| 0001GW | INSECT VENOM PANEL IGG | 12 | ||||
| 0001GX | INACTIVE ASPERGILLUS ANTIBODIES, IMMUNODIFFUSION, SERUM | 12 | ||||
| 0001GY | INHIBIN A | 12 | ||||
| 0001GZ | INHIBIN B | 12 | ||||
| 0001HA | INSULIN | 72 | ||||
| 0001HB | INSULIN AUTOANTIBODY | 12 | ||||
| 0001HC | JAK2 V617F MUTATION ANALYSIS | 96 | ||||
| 0001HD | Kappa/Lambda Light Chains, Total, W/Calculation 24HR Urine | 12 | ||||
| 0001HE | INTRINSIC FACTOR BLOCKING ANTIBODY, W/FLAER(HIGH SENSI | 48 | ||||
| 0001HF | LACOSAMIDE | 12 | ||||
| 0001HG | LACTATE DEHYDROGENASE (LD) ISOENZYME PANEL | 36 | ||||
| 0001HH | LACTIC ACID, PLASMA | 12 | ||||
| 0001HJ | LEAD (VENOUS) | 12 | ||||
| 0001HK | LAMOTRIGINE | 96 | ||||
| 0001HL | LEUKEMIA/LYMPHOMA EVALUATION | 180 | ||||
| 0001HM | LEVETIRACETAM | 24 | ||||
| 0001HN | LIPOPROTEIN (A | 12 | ||||
| 0001HP | LIPOPROTEIN ELECTROPHORESI | 12 | ||||
| 0001HQ | LH | 276 | ||||
| 0001HR | LITHIUM | 120 | ||||
| 0001HS | LIVER FIBROSIS, FIBROTEST-ACTITEST PANEL | 132 | ||||
| 0001HT | LIVER KIDNEY MICROSOMAL (LKM-1) ANTIBODY (IGG) | 24 | ||||
| 0001HU | Lupus Anticoagulant and Cardiolipin AB Panel With Reflexes | 60 | ||||
| 0001HV | LYME DISEASE ANTIBODY WITH REFLEX TO BLOT (IGG,IGM) | 36 | ||||
| 0001HW | LYSOZYME (MURAMIDASE) | 12 | ||||
| 0001HX | LYMPHOCYTE SUBSET PANEL 4 | 144 | ||||
| 0001HY | MEASLES ANTIBODY (IGG) | 408 | ||||
| 0001HZ | Metanephrines, Fractionated, LC/MS/MS, Random Urine | 24 | ||||
| 0001JA | Methylenetetrahydrofolate Reductase, DNA Mutation Analysis | 24 | ||||
| 0001JB | METHYLMALONIC ACID | 72 | ||||
| 0001JC | MITOCHONDRIA M2 ANTIBODY (IGG), EIA | 168 | ||||
| 0001JD | MYCOPLASMA HOMINIS/UREAPLASMA CULTURE | 24 | ||||
| 0001JE | MYASTHENIA GRAVIS PANEL 2 W/REFLEX TO MUSK AB | 24 | ||||
| 0001JF | MUMPS VIRUS ANTIBODY (IGG) | 408 | ||||
| 0001JG | MYOGLOBIN, SERUM | 24 | ||||
| 0001JH | OMEGA-3 AND -6 FATTY ACIDS | 12 | ||||
| 0001JJ | NICOTINE AND COTININE, SERUM/PLASMA | 60 | ||||
| 0001JK | NORTRIPTYLINE | 24 | ||||
| 0001JL | NICOTINE AND COTININE, URINE | 48 | ||||
| 0001JM | OSMOLALITY, SERUM | 36 | ||||
| 0001JN | OSMOLALITY, URINE | 48 | ||||
| 0001JP | OXCARBAZEPINE METABOLITE | 36 | ||||
| 0001JQ | PAROXYSMAL NOCTURNAL HEMOGLOBINURIA(PNH) | 12 | ||||
| 0001JR | PHARMACOGENOMICS PANEL | 12 | ||||
| 0001JS | PHENYTOIN, FREE | 12 | ||||
| 0001JT | PHENYTOIN | 36 | ||||
| 0001JU | PHOSPHATIDIC ACID ANTIBODY (IGA) | 84 | ||||
| 0001JV | PHOSPHATIDIC ACID ANTIBODY (IGG) | 84 | ||||
| 0001JW | PHOSPHATIDIC ACID ANTIBODY (IGM | 84 | ||||
| 0001JX | Phosphatidic Acid Antibody (IGM), Repeat #xpansion Test [371] (92903 | 84 | ||||
| 0001JY | PHOSPHATIDYLCHOLINE ANTIBODIES (IGG, IGA, IGM) | 84 | ||||
| 0001JZ | PHOSPHATIDYLETHANOLAMINE ANTIBODIES (IGG, IGA, IGM) | 84 | ||||
| 0001KA | PHOSPHATIDYLGLYCEROL ANTIBODIES (IGG, IGA, IGM) | 96 | ||||
| 0001KB | PHOSPHATIDYLINOSITOL ANTIBODIES (IGG, IGA, IGM) | 84 | ||||
| 0001KC | PHOSPHATIDYLSERINE ANTIBODIES (IGG, IGA, IGM) | 84 | ||||
| 0001KD | POTASSIUM, 24-HOUR URINE WITHOUT CREATININE | 12 | ||||
| 0001KE | PLATELET ANTIBODY SCREEN (INDIRECT) | 36 | ||||
| 0001KF | PRIMIDONE | 12 | ||||
| 0001KG | POTASSIUM, RANDOM URINE WITHOUT CREATININE | 36 | ||||
| 0001KL | PROGESTERONE | 12 | ||||
| 0001KM | PROLACTIN | 120 | ||||
| 0001KN | PROTEIN C ANTIGEN | 12 | ||||
| 0001KP | PROTEIN C & PROTEIN S, FUNCTIONAL | 132 | ||||
| 0001KQ | PROTEIN C ACTIVITY | 72 | ||||
| 0001KR | PROTEIN ELECTRO,W/TOTAL PROTEIN, REFLEX,IFE,SERUM | 168 | ||||
| 0001KS | PROTEIN ELECTROPHORESIS, 24-HOUR URINE (UPEP) | 48 | ||||
| 0001KT | PROTEIN S ANTIGEN, TOTAL | 12 | ||||
| 0001KU | PROTEIN ELECTROPHORESIS, RANDOM URINE (UPEP) | 72 | ||||
| 0001KV | PROTEIN S ACTIVITY | 60 | ||||
| 0001KW | PROTEIN, TOTAL 24HR URINE | 36 | ||||
| 0001KX | PROTEIN, TOTAL AND PROTEIN ELECTROPHORESIS (747 | 72 | ||||
| 0001KY | PROTEIN, TOTAL URINE RANDOM | 12 | ||||
| 0001KZ | PROTHROMBIN (FACTOR II) 20210G>A MUTATION ANALYSIS | 96 | ||||
| 0001LA | PTH, INTACT WITHOUT CALCIUM | 456 | ||||
| 0001LB | PSA POST PROSTATECTOMY | 12 | ||||
| 0001LC | PTH-RELATED PROTEIN (PTH-RP) | 24 | ||||
| 0001LD | RABIES RFFIT SEROLOGY END POINT TITER (91810 | 12 | ||||
| 0001LE | REFLEX ENDOMYSIAL ANTIBODY SCREEN (IGA | 12 | ||||
| 0001LF | Quantitative Thyroglobulin W/O Thyroglobulin Antibodies | 36 | ||||
| 0001LG | REFLEX TISSUE TRANSGLUTAMINASE ANTIBODY | 36 | ||||
| 0001LH | RISTOCETIN COFACTOR | 12 | ||||
| 0001LJ | RISPERIDONE AND METABOLITE | 12 | ||||
| 0001LK | RHEUMATOID FACTOR | 516 | ||||
| 0001LL | SARS-COV-2 SEROLOGY (COVID-19 | 12 | ||||
| 0001LM | RUBELLA IMMUNE STATUS | 420 | ||||
| 0001LN | SALMONELLA ANTIBODIES | 12 | ||||
| 0001LP | SCA1 (ATXN1 | 12 | ||||
| 0001LQ | SEROTONIN, SERUM | 36 | ||||
| 0001LR | SIROLIMUS, LC/MS/MS | 12 | ||||
| 0001LS | SEX HORMONE BINDING GLOBULIN (SHBG) | 48 | ||||
| 0001LT | SJOGREN'S ANTIBODIES (SS-A,SS-B) | 36 | ||||
| 0001LU | SODIUM WITHOUT CREATININE, 24-HOUR URINE | 12 | ||||
| 0001LV | SM/RNP ANTIBODY | 12 | ||||
| 0001LW | SODIUM, RANDOM URINE WITHOUT CREATININE | 84 | ||||
| 0001LX | STREPTOCOCCUS GROUP A, DNA PROBE (14565 | 12 | ||||
| 0001LY | STREPTOCOCCUS PNEUMONIAE IGG AB (23 SEROTYPES | 12 | ||||
| 0001LZ | SOLUBLE TRANSFERRIN RECEPTOR | 12 | ||||
| 0001MA | STRATIFY JCV (TM) AB (W/INDEX) W/RFLX TO INHIBITION ASSAY | 12 | ||||
| 0001MB | SURESWAB (R), CANDIDIASIS, PCR | 12 | ||||
| 0001MC | SURESWAB(R), VAGINOSIS/VAGINITIS PLUS | 120 | ||||
| 0001MD | T-CELL RECEPTOR (TCR) BETA GENE REARRANGEMENT, PCR | 84 | ||||
| 0001ME | T-CELL RECEPTOR (TCR) GAMMA GENE REARRANGEMENT, PCR | 60 | ||||
| 0001MF | T3 UPTAKE | 12 | ||||
| 0001MG | T3, TOTAL | 72 | ||||
| 0001MH | T4 (THYROXINE), TOTAL | 60 | ||||
| 0001MJ | TACROLIMUS, HIGHLY SENSITIVE, LC/MS/MS | 444 | ||||
| 0001MK | TBG (THYROXINE BINDING GLOBULIN) | 24 | ||||
| 0001ML | TESTOSTERONE, FREE | 252 | ||||
| 0001MM | THEOPHYLLINE | 12 | ||||
| 0001MN | TESTOSTERONE, TOTAL, MALES (ADULT), IMMUNOASSAY | 1176 | ||||
| 0001MP | TESTOSTERONE, FREE (DIALYSIS | 252 | ||||
| 0001MQ | THYROID PEROXIDASE ANTIBODIES | 84 | ||||
| 0001MR | TISSUE TRANSGLUTAMINASE ANTIBODY (IGG) | 12 | ||||
| 0001MS | TISSUE TRANSGLUTAMINASE ANTIBODY (IGG, IGA) | 12 | ||||
| 0001MT | TRICHINELLA IGG ANTIBODY | 36 | ||||
| 0001MU | TOPIRAMATE | 72 | ||||
| 0001MV | TOXOPLASMA ANTIBODIES (IGG,IGM | 12 | ||||
| 0001MW | TOXOPLASMA GONDII ANTIBODY (IGA | 12 | ||||
| 0001MX | TSI (THYROID STIMULATING IMMUNOGLOBULIN) | 24 | ||||
| 0001MY | TTR DNA SEQUENCING TEST | 12 | ||||
| 0001MZ | VALPROIC ACID | 384 | ||||
| 0001NA | VITAMIN A (RETINOL) | 36 | ||||
| 0001NB | VARICELLA-ZOSTER VIRUS ANTIBODY (IGG) | 408 | ||||
| 0001NC | VITAMIN B1 (THIAMINE), PLASMA/SERUM, LC/MS/MS | 276 | ||||
| 0001ND | VITAMIN B2 (RIBOFLAVIN), PLASMA | 48 | ||||
| 0001NE | VITAMIN B3 | 252 | ||||
| 0001NF | VITAMIN B6, PLASMA | 60 | ||||
| 0001NG | VITAMIN C | 12 | ||||
| 0001NH | VITAMIN D, 1,25-DIHYDROXY | 3756 | ||||
| 0001NJ | VITAMIN E (TOCOPHEROL) | 72 | ||||
| 0001NK | VITAMIN K | 12 | ||||
| 0001NL | ZINC | 48 | ||||
| 0001NM | QuantiFERON-TB Gold | 100 |
| Estimated Annual Total: | $ - 0 |
| Estimated Monthly: | $ - 0 |
&"-,Bold"&14PRICE LIST
&"Times New Roman,Bold Italic"Attachment 2 36C25721Q0374 &"Times New Roman,Bold Italic"Price List, Revised 3/12/2021 Page &P of &N
File details come from the government source that posted it. Updated .